Dexcom Inc Receives Positive Analyst Coverage

Dexcom Inc, a medical device company specializing in continuous glucose monitoring systems, has received positive attention from analysts.

Goldman Sachs initiated coverage of the company with a Buy rating and set a price target. RBC maintained an Outperform rating with a similar target.

The expected double-digit growth in the diabetes technology market is driving optimism for the company. Dexcom’s continuous glucose monitor (CGM) is seen as a key player in this space.

The company’s stock price has been affected by broader market trends. However, the overall sentiment remains bullish.

Key Analyst Ratings:

• Goldman Sachs:
  • Rating: Buy
• RBC:
  • Rating: Outperform